Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 470 Shares of Company Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Brophy sold 470 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $391.49, for a total value of $184,000.30. Following the completion of the sale, the chief financial officer owned 45,779 shares of the company’s stock, valued at approximately $17,922,020.71. This trade represents a 1.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, November 2nd, Michael Brophy sold 325 shares of Natera stock. The shares were sold at an average price of $399.99, for a total value of $129,996.75.
• On Wednesday, October 28th, Michael Brophy sold 1,178 shares of Natera stock. The stock was sold at an average price of $426.46, for a total transaction of $502,369.88.
• On Friday, October 30th, Michael Brophy sold 1,906 shares of Natera stock. The stock was sold at an average price of $425.55, for a total transaction of $811,098.30.
• On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The stock was sold at an average price of $426.34, for a total transaction of $510,755.32.
• On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The stock was sold at an average price of $406.00, for a total transaction of $317,086.00.

Natera Trading Up 0.6%

NTRA opened at $391.03 on Thursday. The stock has a market capitalization of $56.36 billion, a PE ratio of -287.52 and a beta of 1.55. Natera, Inc. has a 1-year low of $181.00 and a 1-year high of $437.41. The firm has a 50-day moving average price of $380.30 and a two-hundred day moving average price of $268.64.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. Natera’s quarterly revenue was up 37.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.74) earnings per share. On average, research analysts predict that Natera, Inc. will post -1.14 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on NTRA shares. UBS Group upped their price objective on Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. Wells Fargo & Company lifted their target price on Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Piper Sandler boosted their target price on Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Rothschild & Co Redburn assumed coverage on Natera in a research note on Tuesday, September 8th. They set a “buy” rating and a $385.00 price target on the stock. Finally, Canaccord Genuity Group raised their price target on Natera from $375.00 to $500.00 and gave the company a “buy” rating in a report on Monday, October 19th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $394.31.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Medicare coverage for Signatera in HCC could improve patient access and support adoption of Natera’s cancer-monitoring tests. The coverage milestone adds to the commercial opportunity for its oncology business. Natera Medicare coverage for Signatera in HCC
• Positive Sentiment: New ESMO oncology evidence was described as broadening the case for Natera’s cancer-testing portfolio, potentially reinforcing the longer-term growth story. ESMO data broaden Natera’s oncology case
• Neutral Sentiment: Natera was expected to report earnings on November 5, making results and management’s outlook a near-term catalyst; the preview article did not provide reported results. Natera earnings preview
• Neutral Sentiment: The reported analyst consensus price target was $394.31, close to the share price cited in the provided market background, suggesting limited implied upside from that target alone. Natera consensus target price
• Neutral Sentiment: CFO Michael Brophy sold 1,178 shares under a pre-arranged Rule 10b5-1 plan and retained 48,480 shares. The scheduled nature and relatively small size of the sale may temper its significance as a signal about management’s outlook. CFO share sale report

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently modified their holdings of the business. Trust Co. of Vermont bought a new position in Natera during the second quarter worth about $26,000. Elevation Wealth Partners LLC bought a new stake in shares of Natera in the second quarter worth about $30,000. Continuum Advisory LLC bought a new stake in shares of Natera in the second quarter worth about $33,000. International Assets Investment Management LLC increased its holdings in shares of Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares in the last quarter. Finally, Rakuten Securities Inc. acquired a new stake in shares of Natera during the second quarter worth about $35,000. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.